Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Wermke, Martin; Felip Font, Enriqueta; Gambardella, Valentina; Kuboki, Yasutoshi; Morgensztern, Daniel; Hamed, Zohra Oum’

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Wermke, Martin
dc.contributor.author	Felip Font, Enriqueta
dc.contributor.author	Gambardella, Valentina
dc.contributor.author	Kuboki, Yasutoshi
dc.contributor.author	Morgensztern, Daniel
dc.contributor.author	Hamed, Zohra Oum’
dc.date.accessioned	2022-09-15T07:11:01Z
dc.date.available	2022-09-15T07:11:01Z
dc.date.issued	2022-08
dc.identifier.citation	Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, et al. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Futur Oncol. 2022 Aug;18(24):2639–49.
dc.identifier.issn	1744-8301
dc.identifier.uri	https://hdl.handle.net/11351/8197
dc.description	Acoplador de célula T; Carcinoma neuroendocrino; Cáncer de pulmón de células pequeñas
dc.language.iso	eng
dc.publisher	Future Medicine
dc.relation.ispartofseries	Future Oncology;18(24)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Pulmons - Càncer - Tractament
dc.subject	Tumors neuroendocrins - Tractament
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject.mesh	Small Cell Lung Carcinoma
dc.subject.mesh	Carcinoma, Neuroendocrine
dc.subject.mesh	Antibodies, Bispecific
dc.subject.mesh	/therapeutic use
dc.title	Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.2217/fon-2022-0196
dc.subject.decs	carcinoma de pulmón de células no pequeñas
dc.subject.decs	carcinoma neuroendocrino
dc.subject.decs	anticuerpos biespecíficos
dc.subject.decs	/uso terapéutico
dc.relation.publishversion	https://doi.org/10.2217/fon-2022-0196
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Wermke M] Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Dresden, Germany. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gambardella V] Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. [Kuboki Y] Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. [Morgensztern D] Washington University School of Medicine, St. Louis, MO 63110, USA. [Hamed ZO] Boehringer Ingelheim France S.A.S., Reims, France
dc.identifier.pmid	35815644
dc.identifier.wos	000822742900001
dc.rights.accessrights	info:eu-repo/semantics/openAccess